Search results for "actions"

showing 10 items of 2898 documents

Atenolol interaction with aspirin, allopurinol, and ampicillin.

1983

Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered…

AdultMaleCombination therapyUrinary systemAllopurinolPhysical ExertionAllopurinolBiological AvailabilityBlood PressurePharmacologyPropanolaminesHeart RateAmpicillinmedicineHumansPharmacology (medical)Drug Interactionscardiovascular diseasesPharmacologyAspirinAspirinChemistryAtenololBioavailabilityKineticsBlood pressureAtenololAmpicillinFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man

1976

The effect of repeated administration of tolbutamide on the elimination and anticoagulant action of a single oral dose of dicoumarol 600 mg was studied in four healthy male subjects using a crossover design. In all subjects the plasma concentration of dicoumarol in the postabsorptive phase was lower during concomitant tolbutamide treatment. However, the subjects differed with respect to the elimination kinetics of dicoumarol and the effect of tolbutamide on some of the measured pharmacokinetic paramaters. In two subjects dicoumarol was eliminated by apparent first-order kinetics. Tolbutamide led to a pronounced increase in the elimination rate and a shift in the plasma concentration-respons…

AdultMaleDicumarolmedicine.medical_specialtymedicine.drug_classTolbutamidePharmacologySingle oral dosechemistry.chemical_compoundTolbutamidePharmacokineticsInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyAnticoagulantGeneral MedicineDicoumarolCoumarinCrossover studyPharmacokinetic analysisEndocrinologychemistryHalf-LifeProtein Bindingmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Clinical evaluation of drug-induced hepatitis

2005

Objective: to ascertain the epidemiological characteristics, clinical symptoms, and evolution of drug-induced hepatitis over the last 22 years. Experimental design and subjects: an observational, retrospective study between 1982 and 1993, and prospective study between 1994 and 2003. All patients in our department diagnosed with having drug-induced hepatitis were studied analyzing epidemiological (age, sex, cases per year, hospitalization) and clinical features (previous liver disease, hepatic symptoms, laboratory results), and follow-up (complete recovery or chronicity). Results: a total of 61 patients were diagnosed as having drug-induced hepatitis, 26 men and 35 women (57%), mean age 52.4…

AdultMaleDrugmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEpidemiologyEvolutionmedia_common.quotation_subjectLiver diseaseSex FactorsInternal medicineEpidemiologyHumansMedicineAcute hepatitisProspective cohort studyAgedRetrospective Studiesmedia_commonHepatitisClinical characteristicsbusiness.industryIncidence (epidemiology)Age FactorsGastroenterologyDrugsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryHospitalizationSpainFemaleObservational studyChemical and Drug Induced Liver InjurybusinessRevista Española de Enfermedades Digestivas
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Lack of hepatitis B virus DNA sequences in sera from patients with acute and chronic liver diseases diagnosed as non-A, non-B-hepatitis

2008

— The sera of 15 individuals with transfusion-associated acute or chronic non A, non B hepatitis, which lacked hepatitis B virus markers, were tested for hepatitis B virus DNA by dot blot hybridization test. Three sera of two patients positive in this test, however, also gave positive results when the labeled plasmid was used as probe instead of labeled HBV-DNA, indicating false positive results in the initial test. In conclusion, the data indicated that sera of patients with confirmed non A, non B hepatitis do not contain DNA-sequences in the serum hybridizing with HBV-DNA.

AdultMaleHepatitis B virusAdolescentHepatitis Viral HumanDot blotmedicine.disease_causeChronic liver diseaseVirusPlasmidmedicineHumansFalse Positive ReactionsAgedHepatitis B virusHepatologybiologybusiness.industryMiddle AgedHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis CVirologyHepadnaviridaeDNA ViralImmunologyFemaleViral diseasebusinessLiver
researchProduct

Falsely elevated intraocular pressure due to increased central corneal thickness

1999

PURPOSE: To evaluate whether ocular hypertensive subjects have a higher central corneal thickness than other individuals. METHODS: In this prospective study, 48 subjects with ocular hypertension, 63 patients with open-angle glaucoma, 56 nonglaucomatous patients with diabetes mellitus, and 106 control subjects were evaluated. Corneal thickness was measured by ultrasound pachymetry, and intraocular pressure was determined by Goldmann applanation tonometry. RESULTS: Central corneal thickness was significantly higher in the ocular hypertensive subjects, mean +/- S.D., 592+/-39 microm, than in the patients with glaucoma (536+/-34 microm), the nonglaucomatous patients with diabetes mellitus (550+…

AdultMaleIntraocular pressuremedicine.medical_specialtyprimary open-angle glaucomaAdolescentgenetic structuresEye diseaseOcular hypertensionGlaucomaCorneaCellular and Molecular NeurosciencePredictive Value of TestsCorneaOphthalmologyDiabetes mellitusHumansMedicineFalse Positive ReactionsProspective StudiesCorneal pachymetry[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansProspective cohort studyAgedUltrasonographyAged 80 and overmedicine.diagnostic_testdiabetesbusiness.industryMiddle Agedmedicine.diseaseSensory Systemseye diseasesSurgeryOphthalmologymedicine.anatomical_structureocular hypertensionFemalecentral corneal thicknesssense organsbusinessGlaucoma Open-Angle[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyintraocular pressure
researchProduct

Alterations of mechanical characteristics of human skeletal muscle during strength training

1983

To investigate the influence of strength training on the mechanical characteristics of human skeletal muscle, 14 male subjects went through training of combined heavy concentric and eccentric contractions three times a week for 16 weeks. The strength training program consisted mainly of dynamic exercises for leg extensors with loads of 80 to 120% of one maximum repetition. The force-time curves produced during various vertical jumps were the basis for calculation of various mechanical parameters. In addition to a great increase (p less than 0.001) in maximal isometric force, heavy resistance strength training also caused significant (p less than 0.05-0.01) increases in heights and in variou…

AdultMaleMaterials sciencePhysiologyStrength trainingEccentric contractionsSquatIsometric exerciseConcentricSports MedicinePhysiology (medical)medicineHumansOrthopedics and Sports MedicineLegPhysical Education and TrainingForce levelMusclesPublic Health Environmental and Occupational HealthSkeletal muscleMuscle mechanicsGeneral MedicineAnatomyElasticityBiomechanical Phenomenamedicine.anatomical_structureBiomedical engineeringEuropean Journal of Applied Physiology and Occupational Physiology
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Plasticity of brain wave network interactions and evolution across physiologic states

2015

Neural plasticity transcends a range of spatio-temporal scales and serves as the basis of various brain activities and physiologic functions. At the microscopic level, it enables the emergence of brain waves with complex temporal dynamics. At the macroscopic level, presence and dominance of specific brain waves is associated with important brain functions. The role of neural plasticity at different levels in generating distinct brain rhythms and how brain rhythms communicate with each other across brain areas to generate physiologic states and functions remains not understood. Here we perform an empirical exploration of neural plasticity at the level of brain wave network interactions repre…

AdultMaleNerve netCognitive NeuroscienceNeuroscience (miscellaneous)Sensory systemPlasticityCognitive neurosciencelcsh:RC321-571Young AdultCellular and Molecular NeuroscienceNeuroplasticitymedicineHumanslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal ResearchSlow-wave sleepCerebral CortexNetwork physiologySleep StagesNeuronal PlasticityBrain WaveBrain wave interactions; Network physiology; Neural plasticity; Sleep; Time delay stability; Adult; Brain Waves; Cerebral Cortex; Female; Humans; Male; Nerve Net; Neuronal Plasticity; Sleep; Young Adult; Neuroscience (miscellaneous); Cellular and Molecular Neuroscience; Sensory Systems; Cognitive NeuroscienceNetwork dynamicsBrain WavesSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Sensory Systemsbrain wave interactionsmedicine.anatomical_structureBrain wave interactionFemaletime delay stabilityNerve NetSensory SystemPsychologySleepNeuroscienceHumanNeuroscienceneural plasticityFrontiers in Neural Circuits
researchProduct